Compare Eli Lilly And Co (LLY) vs Skyworks Solutions Inc (SWKS) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Skyworks Solutions (SWKS) trades at $59.83, up 0.88% on the day, with a bearish technical signal but strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue has declined from $5.5B in 2022 to $4.1B in 2025, though profitability metrics like a 41.08% gross margin remain solid. Recent news highlights product launches in AI and EV sectors and an ongoing legal investigation.

The outlook is mixed: analyst consensus is bullish with a $75.88 price target (58.34% buy ratings), but technicals and declining revenue pose risks. Key opportunities include diversification beyond mobile chips and AI-driven demand, while risks involve customer concentration, margin pressure, and legal scrutiny. The stock offers a dividend yield above 4%, supported by cash flow.